Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Anai

Showing results (41-50 of 175) with videos related to

Pageof 18
Sort By:
Anticancer Research|May 2, 2018
A Genitourinary Cancer-specific Scoring System for the Prediction of Survival in Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial CarcinomaTakuya Owari, Makito Miyake, Yasushi Nakai, et al.
Andrologia|October 25, 2021
Erectile dysfunction and sexual quality of life in patients who underwent low-dose-rate brachytherapy alone for prostate cancerYasushi Nakai, Nobumichi Tanaka, Isao Asakawa, et al.
Research and Reports in Urology|April 1, 2021
Impact of Radical Nephrectomy and Partial Nephrectomy on Actual Estimated Overall Survival Compared to Life Expectancy in Patients with Renal Cell CarcinomaShunta Hori, Nobumichi Tanaka, Kota Iida, et al.
Cancer Research|March 19, 2009
A novel human AlkB homologue, ALKBH8, contributes to human bladder cancer progressionKeiji Shimada, Mitsutoshi Nakamura, Satoshi Anai, et al.
Oncology Reports|August 31, 2016
Clinical significance of α‑ and β‑Klotho in urothelial carcinoma of the bladderShunta Hori, Makito Miyake, Sayuri Onishi, et al.
Internal Medicine (Tokyo, Japan)|September 15, 2012
Carboplatin plus paclitaxel in the successful treatment of advanced inflammatory myofibroblastic tumorNaoki Kubo, Taishi Harada, Satoshi Anai, et al.
BMC Cancer|May 13, 2008
Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapyJohn M Pendleton, Winston W Tan, Satoshi Anai, et al.
Journal of Contemporary Brachytherapy|November 22, 2019
Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancerYasushi Nakai, Nobumichi Tanaka, Isao Asakawa, et al.
Radiation Oncology (London, England)|December 30, 2014
Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidilNobumichi Tanaka, Kazumasa Torimoto, Isao Asakawa, et al.
Brachytherapy|February 7, 2018
Comparison of chronological changes in urinary function in patients who underwent low-dose-rate brachytherapy for prostate cancer-A randomized controlled trial of alpha-1 adrenoceptor antagonist alone versus combination with cyclooxygenase-2 inhibitorNobumichi Tanaka, Kazumasa Torimoto, Isao Asakawa, et al.
Pageof 18

Showing results (41-50 of 175) with videos related to

Sort By:
Pageof 18
Anticancer Research|May 2, 2018
A Genitourinary Cancer-specific Scoring System for the Prediction of Survival in Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial CarcinomaTakuya Owari, Makito Miyake, Yasushi Nakai, et al.
Andrologia|October 25, 2021
Erectile dysfunction and sexual quality of life in patients who underwent low-dose-rate brachytherapy alone for prostate cancerYasushi Nakai, Nobumichi Tanaka, Isao Asakawa, et al.
Research and Reports in Urology|April 1, 2021
Impact of Radical Nephrectomy and Partial Nephrectomy on Actual Estimated Overall Survival Compared to Life Expectancy in Patients with Renal Cell CarcinomaShunta Hori, Nobumichi Tanaka, Kota Iida, et al.
Cancer Research|March 19, 2009
A novel human AlkB homologue, ALKBH8, contributes to human bladder cancer progressionKeiji Shimada, Mitsutoshi Nakamura, Satoshi Anai, et al.
Oncology Reports|August 31, 2016
Clinical significance of α‑ and β‑Klotho in urothelial carcinoma of the bladderShunta Hori, Makito Miyake, Sayuri Onishi, et al.
Internal Medicine (Tokyo, Japan)|September 15, 2012
Carboplatin plus paclitaxel in the successful treatment of advanced inflammatory myofibroblastic tumorNaoki Kubo, Taishi Harada, Satoshi Anai, et al.
BMC Cancer|May 13, 2008
Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapyJohn M Pendleton, Winston W Tan, Satoshi Anai, et al.
Journal of Contemporary Brachytherapy|November 22, 2019
Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancerYasushi Nakai, Nobumichi Tanaka, Isao Asakawa, et al.
Radiation Oncology (London, England)|December 30, 2014
Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidilNobumichi Tanaka, Kazumasa Torimoto, Isao Asakawa, et al.
Brachytherapy|February 7, 2018
Comparison of chronological changes in urinary function in patients who underwent low-dose-rate brachytherapy for prostate cancer-A randomized controlled trial of alpha-1 adrenoceptor antagonist alone versus combination with cyclooxygenase-2 inhibitorNobumichi Tanaka, Kazumasa Torimoto, Isao Asakawa, et al.
Pageof 18